Vertex Pharmaceuticals Incorporated - Common Stock (VRTX)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 198% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 20.4% with 32.9% net margin
- Revenue growing at 9% annually
Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $119.2 billion . Key value metrics: P/E ratio 31.3, P/B ratio 6.39, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Vertex Pharmaceuticals Incorporated - Common Stock — Fundamental Analysis Summary
Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) is currently trading 198% above its Graham Number of $157.41, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 31.3x.
On financial health, VRTX shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 20.4% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.37.
StockPik's composite Value Score for VRTX is 59/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VRTX reports a high gross margin of 86.4% (sector average: 33.5%) and a strong operating margin of 35.3%.
VRTX shows revenue growing at 9% year-over-year, with earnings growing at 838%.